WO2007022041A3 - Mutations and polymorphisms of hdac3 - Google Patents
Mutations and polymorphisms of hdac3 Download PDFInfo
- Publication number
- WO2007022041A3 WO2007022041A3 PCT/US2006/031560 US2006031560W WO2007022041A3 WO 2007022041 A3 WO2007022041 A3 WO 2007022041A3 US 2006031560 W US2006031560 W US 2006031560W WO 2007022041 A3 WO2007022041 A3 WO 2007022041A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hdac3
- mutations
- mutant
- polymorphisms
- various aspects
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Abstract
This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the HDAC3 gene. The invention provides new HDAC3 mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the HDAC3 mutations of the invention, expression vectors encoding the HDAC3 mutant polypeptides of the invention and organisms that express the HDAC3 mutant and polymorphic polynucleotides and/or HDAC3 mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the HDAC3 mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70748305P | 2005-08-11 | 2005-08-11 | |
US60/707,483 | 2005-08-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007022041A2 WO2007022041A2 (en) | 2007-02-22 |
WO2007022041A3 true WO2007022041A3 (en) | 2010-09-02 |
Family
ID=37491815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/031560 WO2007022041A2 (en) | 2005-08-11 | 2006-08-10 | Mutations and polymorphisms of hdac3 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007022041A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007050655A2 (en) * | 2005-10-24 | 2007-05-03 | Novartis Ag | Combination of histone deacetylase inhibitors and radiation |
EP2120948A1 (en) * | 2007-02-13 | 2009-11-25 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives |
TW201006823A (en) * | 2008-07-14 | 2010-02-16 | Novartis Ag | Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis |
CN110151830A (en) * | 2019-05-27 | 2019-08-23 | 嘉兴市爵拓科技有限公司 | Water melon young fruit and Garbo melon young fruit are used to prepare the purposes of the medical composition of controlling gene |
WO2023034440A1 (en) | 2021-09-01 | 2023-03-09 | Case Western Reserve University | Treatment of neurodegenerative diseases with hdac inhibitors |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020061860A1 (en) * | 2000-03-24 | 2002-05-23 | Zuomei Li | Antisense oligonucleotide inhibition of specific histone deacetylase isoforms |
WO2004053066A2 (en) * | 2002-12-06 | 2004-06-24 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy |
US20040197888A1 (en) * | 2002-12-31 | 2004-10-07 | Armour Christopher D. | Alternatively spliced isoforms of histone deacetylase 3 (HDAC3) |
WO2005103703A2 (en) * | 2004-04-23 | 2005-11-03 | Rigshospitalet, Copenhagen University Hospital | Use of novel biomarkers for detection of testicular carcinoma in situ and derived cancers in human samples |
-
2006
- 2006-08-10 WO PCT/US2006/031560 patent/WO2007022041A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020061860A1 (en) * | 2000-03-24 | 2002-05-23 | Zuomei Li | Antisense oligonucleotide inhibition of specific histone deacetylase isoforms |
WO2004053066A2 (en) * | 2002-12-06 | 2004-06-24 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy |
US20040197888A1 (en) * | 2002-12-31 | 2004-10-07 | Armour Christopher D. | Alternatively spliced isoforms of histone deacetylase 3 (HDAC3) |
WO2005103703A2 (en) * | 2004-04-23 | 2005-11-03 | Rigshospitalet, Copenhagen University Hospital | Use of novel biomarkers for detection of testicular carcinoma in situ and derived cancers in human samples |
Non-Patent Citations (6)
Title |
---|
ACHARYA, MILIN R. ET AL: "Rational development of histone deacetylase inhibitors as anticancer agents: A review", MOLECULAR PHARMACOLOGY, vol. 68, no. 4, 14 June 2005 (2005-06-14), pages 917 - 932, XP002423309 * |
EMILIANI, STEPHANE ET AL: "Characterization of a human RPD3 ortholog, HDAC3", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA , 95(6), 2795-2800 CODEN: PNASA6; ISSN: 0027-8424, 1998, XP002435779 * |
KRISTELEIT R ET AL: "HISTONE MODIFICATION ENZYMES: NOVEL TARGETS FOR CANCER DRUGS", EXPERT OPINION ON EMERGING DRUGS, ASHLEY PUBLICATIONS, GB, vol. 9, no. 1, 2004, pages 135 - 154, XP008041959, ISSN: 1472-8214 * |
LILLEBERG STAN L: "IN-DEPTH MUTATION AND SNP DISCOVERY USING DHPLC GENE SCANNING", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 6, no. 2, March 2003 (2003-03-01), pages 237 - 252, XP008078438, ISSN: 1367-6733 * |
MILLER, THOMAS A.: "Patent status of histone deacetylase inhibitors", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 14, no. 6, 2004, pages 791 - 804, XP002423308 * |
MONNERET, CLAUDE: "Histone deacetylase inhibitors", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, no. 1, 9 December 2004 (2004-12-09), pages 1 - 13, XP004708959 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007022041A2 (en) | 2007-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007016532A3 (en) | Mutations and polymorphisms of hdac4 | |
WO2006130527A3 (en) | Mutations and polymorphisms of fibroblast growth factor receptor 1 | |
WO2009132058A3 (en) | Levels of bcma protein expression on b cells and use in diagnostic methods | |
WO2005033652A3 (en) | Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol | |
WO2002086448A3 (en) | Detection of microsatellite instability and its use in diagnosis of tumors | |
WO2005082042A3 (en) | Therapeutic methods employing nitric oxide precursors | |
HK1093674A1 (en) | Anti-april monoclonal antibody and its use for the treatment of an immune related disease or cancer | |
EP2293074A3 (en) | Method for diagnosing neuro-degenerative disease | |
IL182540A0 (en) | Method of assaying alzheimer's disease and diagnostic reagent | |
NZ600235A (en) | Methods and compositions for the assessment of drug response | |
WO2001040517A3 (en) | Evaluating and predicting clinical outcomes by gene expression analysis | |
EP2287340A3 (en) | Method for diagnosis and treatment of a mental disease | |
EP2503338A3 (en) | CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies | |
WO2006110478A3 (en) | Mutations and polymorphisms of epidermal growth factor receptor | |
WO2006096737A3 (en) | Diagnostic and therapeutic target for macular degeneration | |
WO2007022041A3 (en) | Mutations and polymorphisms of hdac3 | |
ATE432997T1 (en) | THERAPY MONITORING FOR TUMORS USING ACC133 MRNA | |
WO2005118403A3 (en) | Methods for detecting gene expression in peripheral blood cells and uses thereof | |
TW200716764A (en) | Bladder cancer biomarkers and uses thereof | |
WO2007030455A3 (en) | Mutations and polymorphisms of hdac10 | |
WO2006003414A3 (en) | Biomarkers of alzheimer's disease | |
AU2006228990A8 (en) | A method of diagnosis and treatment and agents useful for same | |
WO2007038073A3 (en) | Mutations and polymorphisms of hdac11 | |
WO2007030454A3 (en) | Mutations and polymorphisms of hdac9 | |
WO2007058992A3 (en) | Mutations and polymorphisms of hdac6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06789736 Country of ref document: EP Kind code of ref document: A2 |